We asked biotech stakeholders about some of the key developments going on in their markets for a special edition on the industry.
Speaking about the sector in America, Brent Erickson, Executive Vice President, Industrial & Environmental, at the Biotechnology Innovation Organization, told us: “In 2018, the United States’ leadership position in the commercialisation and market introduction of industrial biotech products will be challenged by Europe and Asia. As industrial biotechnology has diversified into high-value consumer products, specialty ingredients such as flavors and fragrances, and nutritional ingredients, countries have begun to aggressively lure the industry to capitalise on the economic and technological growth potential.”
While Roger Kilburn, CEO of the Glasgow-headquartered Industrial Biotechnology Innovation Centre (IBioIC), expects the domestic market in Scotland to capitalise on the country’s abundance of natural assets.
He said: “In Scotland we will be looking to leverage the significant and unique natural, physical and human assets we have to focus on the most attractive opportunities for developing IB. This will include marine biotech, carbon capture and utilisation technologies and valorisation of our municipal and industrial waste streams.”